Skip to main content
OpenTrials
Completed

NCT Number: NCT04682678

Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease

Our project is based on the fundamental hypothesis that epidural spinal cord stimulation (SCS) improves Freezing of gait (FOG) in patients with Parkinson's disease. In eight patients implantation of electrodes for SCS at the epidural thoracic level will be performed under general anaesthesia.

Evaluation of gait and motor symptoms will be performed with and without stimulation, after a 3-month period for each of the stimulation conditions.This is a pilot, single centre, prospective, randomized, double blinded, cross-over study.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Patients will be selected in the Movement Disorders Unit, Department of Neurology, University Hospital Grenoble. A preoperative assessment with gait assessment, clinical evaluation and Non-Motor Symptoms assessment will be realized. The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.After the first post-operative month the patient will be randomized to the STIM ON condition (stimulation on, with the most effective parameters) or STIM OFF (without stimulation). The randomization will be performed in a double blinded fashion, by a neurologist working in open and not participating in the evaluations. After 3 months, the patient will be evaluated in a double blind condition, and the stimulation condition will be crossed for another period of 3 months. At the end of this second 3-month period, the patient will be again double-blind assessed. After this evaluation, the patient will enter the open phase of the study for a period of 6 months. For this last phase of the study, under STIM ON condition, an optimization of the stimulation settings will be realized, if necessary. At the end of this 6-month period of stimulation, the patient will be evaluated one last time. At all visits, clinical and gait evaluations will be carried out under chronic dopaminergic treatment. No change in antiparkinsonian treatment will be allowed during the entire study. Gait and clinical assessment will be performed at baseline and at the end of each double blinded phase and at 1-year follow-up. For the double-blind study the patient, the neurologist who performs the clinical evaluation and the expert who performs the gait test and analysis will be blind to the stimulation condition.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with diagnosis of idiopathic PD
  • Aged 50-85 years
  • Having a FOG (score> 14 at New-FOG-Questionnaire; score> = 1 at item 2.13 of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale) despite the optimization of medical treatment
  • Drug treatment stable for at least 2 months
  • Able to give written consent.

Exclusion criteria

  • Pain syndrome (score> = 2 at item 1.9 of the MDS-UPDRS II)
  • Psychosis
  • Severe depression
  • Severe cognitive impairment (Mini Mental Score Examination <19)
  • Patient receiving STN DBS treatment
  • Presence of other neurological or medical pathologies interfering with walking
  • Subject in period of exclusion from another study
  • Subject under administrative or judicial supervision
  • Subject who cannot be contacted in an emergency.
  • Person with any administrative or judicial measure of deprivation of rights and liberty

Treatment and study plan

Implantation of electrodes for Spinal cord stimulation

Procedure

The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.

Primary outcomes

  1. frequency and duration of Freezing Of Gait (FOG) episodes, objective

    Time frame: Month 6

    gait testing

Secondary outcomes

  1. frequency and duration of Freezing Of Gait (FOG) episodes, subjective 1

    Time frame: Month 12

    New FOG-questionnaire (NFOG-Q)

  2. frequency and duration of Freezing Of Gait (FOG) episodes, subjective 2

    Time frame: Month 12

    patient diary

  3. impact of spinal cord stimulation on FOG, long term outcome

    Time frame: Month 12

    New Freezing Of Gait-questionnaire (NFOG-Q)

  4. impact of spinal cord stimulation on quality of life, long term outcome

    Time frame: Month 12

    Parkinsons disease questionnaire (PDQ39)

  5. impact of SCS on gait during a dual cognitive-motor task test

    Time frame: Month 12

    New FOG-questionnaire (NFOG-Q)

  6. impact of SCS on other non-motor symptoms

    Time frame: Month 12

    SCales for Outcomes in PArkinson's disease - Autonomic Dysfunction (SCOPA-AUT)

  7. impact of SCS on gait during timed up and go test

    Time frame: Month 12

    timed up and go test

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease: a Pilot Study

Acronym: SCM-PARK

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Dec 24, 2020
Registry last updated
Oct 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.